The Phoenix Molecular Designs Team attended the Global Life Science Partnering & Investor Conference by Biocom California.
On January 6 at 1:30 pm, Dr. Sandi Dunn will lead a Panel Discussion on Getting to Regulatory Approval alongside industry experts Marshall Fordyce, Orr Inbar, Thomas Lonngren and Pascal Touchon.
Our esteemed collaborators, Kalien M. from Stanford University School of Medicine, and Tim W. from Washington University School of Medicine in St. Louis presented leading-edge studies utilizing PMD-026. Their research underscores promising data supporting the efficacy of PMD-026 in treating myeloid cancers, including Acute Myeloid Leukemia (AML).
Founder and CEO, Dr. Sandi Dunn, presented insights from Phoenix Molecular Designs’ late-breaking poster presentation. Delving into the PMD-026 Phase I/Ib study, she discussed how patient selection for high RSK2 expression could be pivotal for achieving enhanced Progression-Free Survival (PFS) in metastatic breast cancer. Find a link to the poster here: Patient Selection for High RSK2 Expression is Key for Achieving Improved PFS in Metastatic Breast Cancer in the PMD-026 Phase I/Ib Study
Congratulations to Phoenix Molecular Designs’ long-standing advisory board member, Dr. Alan Ashworth, for winning the prestigious American Society of Clinical Oncology (ASCO) 2023 Science of Oncology Award!
PMD-026 was presented at the American Society of Hematology (ASH) 2022 Annual Meeting where Stephen Oh's lab presented their data - Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies.
Phoenix Molecular Designs were excited to attend and present its poster at the San Antonio Breast Cancer Symposium this year. Find a link to the poster here: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first-in-class RSK inhibitor.
During Breast Cancer Awareness Month, Dr. Sandi Dunn was asked by The Province where her passion and determination to beat breast cancer comes from. Read the story here: https://theprovince.com/opinion/dr-sandi-dunn-i-lost-my-sister-in-law-to-the-most-aggressive-and-deadliest-form-of-breast-cancer
Held annually in Napa and Europe, the invitation only Biotech CEO Summits provide high-value, relationship-building opportunities through informal discussions where personal knowledge, insights, and ideas are exchanged with peers.
Please join us as we present our poster at this year’s AACR Annual General Meeting 2022.
Join us at the SABCS 2022, as we announce the results from our First-in-Human Expansion Study of PMD-026 in Metastatic Triple-Negative Breast Cancer (TNBC) Patients. Our results highlighted that PMD-026 doubled progression free survival in metastatic TNBC patients relative to chemotherapy with a well-tolerated safety profile.
In-person celebration of the Forbes 50 Over 50 award recipients including PhoenixMD Founder and CEO, Dr. Sandra Dunn. The event will be held at the Forbes on Fifth event space in New York City for an afternoon of connection, merriment and inspiration featuring an intimate conversation with none other than the First Lady of the United States Jill Biden.
To celebrate Breast Cancer Awareness Month, we were honored to help sponsor YSC San Diego's Self Care Gathering 2021. Every October, YSC San Diego has a tradition of gathering and honoring young adults with love and pampering.
The Young Survivor Coalition (YSC) is an organization dedicated to all young breast cancer survivors and their co-survivor support network.
The first TNBC Drug Development Digital Summit begins tomorrow. Our Founder and CEO, Dr. Sandra Dunn, will be speaking on Thursday, April 29 at 8:30 am PST.
Don't miss her and other industry leaders from MD Anderson Cancer Center, Stanford University, Triple Negative Breast Cancer Foundation, Moffit Cancer Center, and Tigerlily Foundation speak about the discovery and development of TNBC treatments to reach patients in need.
Please join us as we present our poster at this year’s AACR Annual Meeting 2021.
Please join us as we present our poster at this years virtually held SABCS 2020
We have been selected as one of 35+ companies, and only 1 of 5 Canadian companies, to present at the Texas Life Science Forum, Co-Hosted by Rice Alliance and BioHouston #TXLifeScienceForum
Please join our CEO Dr Sandi Dunn, a guest speaker, at this important educational event for patients and supporters of women with metastatic breast cancer.
Learn more about this event here
PhoenixMD will be joining other breast cancer researchers, physicians and thought leaders at this key event. Keep an eye out for our poster presentation about PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for the treatment of triple negative breast cancer (TNBC).
Join the Komen's Race for the Cure®, which helps to raise important funds that are invested in ground breaking research. You can help play a critical role in furthering major advancements in breast cancer
Come and visit our booth at this event!
Details about the event in San Diego can be found here
More than 82,000 Canadians are expected to be involved in this fundraising event that is dedicated to changing the future of breast cancer.
Details about the event in Vancouver can be found here
In honour of Childhood Cancer Awareness month, we would like to take a moment to thank the Michael Cuccione Foundation who has kept Michael's vision of ending cancer through research ablaze. They raised an astounding $1m for the BCCHRI.
Photo Credit: Silvester Law.
Please keep an eye out for our CEO Dr. Sandra Dunn, who will be presenting the most recent work being done here at Phoenix Molecular Designs towards our First in Human Clinical Trial
Please join us at the Biotech Showcase 2019 Conference being held at the Hilton San Francisco. Our CEO Dr. Sandra Dunn will be presenting the latest exciting updates on our progress towards clinical trials for PMD-026, our promising treatment for Triple Negative Breast Cancer.
2024© Phoenix Molecular Designs
